American Association for Cancer Research
Browse
15357163mct210224-sup-262135_3_supp_7508400_r1z352.pptx (275.82 kB)

Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity

Download (275.82 kB)
figure
posted on 2023-04-03, 18:45 authored by Yiyu Dong, Yongxing Gong, Fengshen Kuo, Vladimir Makarov, Ed Reznik, Gouri J. Nanjangud, Omer Aras, Huiyong Zhao, Rui Qu, James A. Fagin, Eric J. Sherman, Bin Xu, Ronald Ghossein, Timothy A. Chan, Ian Ganly

A, Combination treatment of XTC.UC1 with rapamycin and the pan-AKT inhibitor MK2206 and MEK inhibitor PD325902. B, Cell proliferation assay of XTC.UC1 cells treated with rapamycin or AZD8055 alone and in combination with MK2206 or PD325902. C, Immunoblot analysis of mTOR signaling at 5 hours after treatment with rapamycin or AZD 8055 alone and in combination with MK2206 or PD325902. Rapamycin combined with MK2206 did not further reduce cell proliferation, despite inhibition of p-AKT(S473). Rapamycin combined with PD325901 did not result in further reduction of cell proliferation.

Funding

NIH SPORE grant

NIH

NCI

History

ARTICLE ABSTRACT

Hurthle cell carcinomas (HCCs) are refractory to radioactive iodine and unresponsive to chemotherapeutic agents, with a fatality rate that is the highest among all types of thyroid cancer after anaplastic thyroid cancer. Our previous study on the genomic landscape of HCCs identified a high incidence of disruptions of mTOR pathway effectors. Here, we report a detailed analysis of mTOR signaling in cell line and patient-derived xenograft mouse models of HCCs. We show that mTOR signaling is upregulated and that targeting mTOR signaling using mTOR inhibitors suppresses tumor growth in primary tumors and distant metastasis. Mechanistically, ablation of mTOR signaling impaired the expression of p-S6 and cyclin A2, resulting in the decrease of the S phase and blocking of cancer cell proliferation. Strikingly, mTOR inhibitor treatment significantly reduced lung metastatic lesions, with the decreased expression of Snail in xenograft tumors. Our data demonstrate that mTOR pathway blockade represents a novel treatment strategy for HCC.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC